FDA Approves Roivant’s Lisraya (brepocitinib) as First Oral Drug for Dermatomyositis
The FDA approved Roivant’s Lisraya (brepocitinib), the first oral dual TYK2/JAK1 inhibitor, to treat dermatomyositis in adults.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Dermatomyositis
FDA approves brepocitinib, the first oral drug for dermatomyositis in adults
The FDA approved LISRAYA (brepocitinib), the first oral TYK2/JAK1 inhibitor for treating adult dermatomyositis, on August 27, 2026.
Read More